| 2.65 0.17 (6.85%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.28 | 1-year : | 3.7 |
| Resists | First : | 2.81 | Second : | 3.17 |
| Pivot price | 2.6 |
|||
| Supports | First : | 2.23 | Second : | 1.85 |
| MAs | MA(5) : | 2.53 |
MA(20) : | 2.61 |
| MA(100) : | 2.33 |
MA(250) : | 1.69 |
|
| MACD | MACD : | 0 |
Signal : | 0  |
| %K %D | K(14,3) : | 20 |
D(3) : | 18.3 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 3.27 | Low : | 0.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CNTB ] has closed below upper band by 43.2%. Bollinger Bands are 25.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.58 - 2.59 | 2.59 - 2.61 |
| Low: | 2.43 - 2.44 | 2.44 - 2.46 |
| Close: | 2.46 - 2.48 | 2.48 - 2.5 |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Tue, 03 Mar 2026
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance
Sat, 14 Feb 2026
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Mon, 12 Jan 2026
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 - Yahoo Finance
Tue, 23 Dec 2025
Discovering Connect Biopharma Holdings And 2 Other Promising Penny Stocks - simplywall.st
Mon, 24 Nov 2025
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 1.277e+007 (%) |
| Held by Institutions | 38.4 (%) |
| Shares Short | 272 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.469e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -110 % |
| Return on Assets (ttm) | 481.2 % |
| Return on Equity (ttm) | -38.7 % |
| Qtrly Rev. Growth | 762000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 298820 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|